ZLAB vs. TARO, KURA, DAWN, AVDL, ARDX, DVAX, SUPN, EWTX, PTGX, and ANIP
Should you be buying Zai Lab stock or one of its competitors? The main competitors of Zai Lab include Taro Pharmaceutical Industries (TARO), Kura Oncology (KURA), Day One Biopharmaceuticals (DAWN), Avadel Pharmaceuticals (AVDL), Ardelyx (ARDX), Dynavax Technologies (DVAX), Supernus Pharmaceuticals (SUPN), Edgewise Therapeutics (EWTX), Protagonist Therapeutics (PTGX), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical preparations" industry.
Zai Lab (NASDAQ:ZLAB) and Taro Pharmaceutical Industries (NYSE:TARO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, community ranking, profitability and risk.
Taro Pharmaceutical Industries has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.
Taro Pharmaceutical Industries has a net margin of 7.48% compared to Zai Lab's net margin of -116.45%. Taro Pharmaceutical Industries' return on equity of 3.26% beat Zai Lab's return on equity.
Zai Lab has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Taro Pharmaceutical Industries has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.
Zai Lab currently has a consensus price target of $64.22, suggesting a potential upside of 219.84%. Taro Pharmaceutical Industries has a consensus price target of $43.00, suggesting a potential upside of 1.65%. Given Zai Lab's stronger consensus rating and higher possible upside, equities analysts clearly believe Zai Lab is more favorable than Taro Pharmaceutical Industries.
In the previous week, Zai Lab had 10 more articles in the media than Taro Pharmaceutical Industries. MarketBeat recorded 14 mentions for Zai Lab and 4 mentions for Taro Pharmaceutical Industries. Zai Lab's average media sentiment score of 0.75 beat Taro Pharmaceutical Industries' score of 0.67 indicating that Zai Lab is being referred to more favorably in the media.
Taro Pharmaceutical Industries received 68 more outperform votes than Zai Lab when rated by MarketBeat users. However, 63.58% of users gave Zai Lab an outperform vote while only 61.80% of users gave Taro Pharmaceutical Industries an outperform vote.
41.7% of Zai Lab shares are owned by institutional investors. Comparatively, 91.4% of Taro Pharmaceutical Industries shares are owned by institutional investors. 5.2% of Zai Lab shares are owned by company insiders. Comparatively, 13.8% of Taro Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Taro Pharmaceutical Industries beats Zai Lab on 10 of the 18 factors compared between the two stocks.
Get Zai Lab News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
